AAV-driven human BAG3 overexpression unexpectedly exacerbate heart failure in a LMNAH222P DCM mice model
Dilated cardiomyopathy (DCM) is major cause of heart failure with myocardial systolic dysfunction and ventricular dilatation. In the 30% monogenic forms of DCM, up to 50 genes with causal mutations have been reported potentially leading to protein misfolding and structure/function alteration. One of...
Saved in:
| Published in: | Archives of Cardiovascular Diseases Supplements 2022-06, Vol.14 (2), p.192-192 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | eng |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Dilated cardiomyopathy (DCM) is major cause of heart failure with myocardial systolic dysfunction and ventricular dilatation. In the 30% monogenic forms of DCM, up to 50 genes with causal mutations have been reported potentially leading to protein misfolding and structure/function alteration. One of the well-established causative genes is BAG3, encoding a co-chaperone playing a key role in autophagy, an essential cellular mechanism involved in proteostasis. Thereby, genetic mutations associated with protein misfolding or aggregation could act through a common proteotoxic mechanism that could be balanced by BAG3-dependant autophagy.
Here, our aim was to demonstrate that cardiac restricted BAG3 overexpression could be a therapeutic approach to stop or reverse the DCM phenotype observed in a mouse model knocked-in for a DCM causative LMNA mutation.
Echocardiographic function assessment of two groups of LmnaH222P/H222P mice, either injected with cardiotropic AAV9 expressing the human cDNA Hs-BAG3 or GFP (control), was carried out and followed by biochemistry and immunofluorescence analysis of cardiac tissue.
Hs-BAG3 overexpression was significant and specific to heart tissue at both the protein and transcript levels. Unexpectedly Hs-BAG3-injected mice present altered life expectancy with early signs of heart failure from the age of 6 weeks compare to 12 weeks for AAV-GFP injected controls. Based on the known drastic deleterious cardiac effect of Lmna KO in mice, we hypothesized an increased lamin A/C degradation in LmnaH222P/H222P mice. However, using immunoblotting and immunofluoresence, no difference in lamin A/C protein levels or localization was observable in AAV-HsBAG3 expressing mice hearts.
In the LmnaH222P/H222P mouse model, we highlighted a strong adverse effect of Hs-BAG3 expression in heart tissue, but not associated with increased degradation of lamin A/C. Since BAG3 gene therapy is being evaluated to cure heart failure, it would be of particular interest to study the underlining mechanisms of this unanticipated result. |
|---|---|
| ISSN: | 1878-6480 1878-6502 |